A股異動 | 中藥股持續走強 政策大力支持 創新型中藥獲批數量創新高
格隆匯12月22日丨中藥股持續走強,隴神戎發、貴州百靈和龍津藥業強勢漲停。2020年9月,國家藥監局新發布的《中藥註冊分類及申報資料要求》明確了中藥註冊分類標準,將中藥分為中藥創新藥、中藥改良型新藥、古代經典名方複方、同名同方藥這4類。據不完全統計,2021年至今創新型中藥獲批數量達到11個,創近五年新高。新冠肺炎疫情發生後,中醫藥全面參與疫情防控救治,作出了重要貢獻。同時,中藥板塊重磅支持政策不斷,屬於政策支持方向,如2021年2月國務院出台《關於加快中醫藥特色發展的若干政策措施》,6月30日國家衞健委等聯合制度《關於進一步加強綜合醫院中醫藥工作推動中西醫協同發展的意見》,7月7日五部門共同制定《中醫藥文化傳播行動實施方案(2021-2025年)》等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.